Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award

Published on by Oncology

Ms. Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award 

Student | Sahand University of Technology | Iran

Ms. Ayda Ahmadi is an emerging young researcher in biomedical and pharmaceutical engineering whose academic performance, early research productivity, and strong technical training collectively position her as a promising candidate for a Best Researcher Award. Currently pursuing her M.Sc. in Chemical Engineering with a specialization in Pharmaceutical Engineering at Sahand University of Technology, she holds a solid academic foundation built on a high-performing B.Sc. in Biomedical Engineering (Biomaterials) from Khayyam University. Her hands-on experience includes two extensive 240-hour internships at Samen Pharmaceutical Company—where she gained valuable skills in pharmaceutical formulation, sterile production systems, GMP-based quality control, and laboratory documentation—and in a Dental Prosthesis Laboratory, where she developed practical expertise in biomaterials fabrication relevant to tissue engineering and biomedical device applications. Ayda’s research output reflects her focus on advanced drug delivery systems, nanotechnology, and biomaterials, demonstrated through significant works such as the preparation and characterization of silica nanoparticles and aerogels for smart drug delivery, the design of targeted nanocarriers for anticancer drug delivery to pancreatic tumors, and the study of calcium sulfate for treating bone infections in diabetic patients. With manuscripts submitted and under review, she shows early publication initiative and a clear commitment to building a strong scientific portfolio. Her technical proficiency across COMSOL Multiphysics, MATLAB, Aspen HYSYS, OriginPro, and data management tools further enhances her research capability, supported by multiple certifications. Ayda’s research interests—spanning nanostructure functionalization, controlled antibiotic release, and biomedical applications of engineered materials—align strongly with global research priorities in precision medicine and therapeutic innovation. Motivated to participate in international conferences and collaborative projects, she demonstrates ambition, discipline, and scientific curiosity, making her a suitable and competitive candidate for recognition in young researcher or early-career researcher award categories.

Profile: ORCID

Featured Publications

  1. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Preparation, characterization, and application of silica nanoparticles and silica aerogel in smart drug delivery systems. Manuscript submitted for publication.

  2. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Design and development of smart nanocarriers for targeted delivery of anticancer drugs to pancreatic tumors: A review study. Manuscript under review.

  3. Ahmadi, A. (2024). Investigation of the effect of calcium sulfate in the treatment of bone infections in diabetic patients. Unpublished research project, Khayyam University.

  4. Ahmadi, A. (2024). Surface modification of silica aerogel for drug delivery in the treatment of bone infection in diabetic patients. Unpublished research study, Sahand University of Technology.

  5. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2024). Development of functionalized nanostructures for controlled antibiotic release in infectious diseases. Unpublished manuscript.

Ms, Ayda Ahmadi’s research advances next-generation drug delivery systems and biomaterial-based therapeutics, contributing to safer, more effective treatments for cancer and infectious diseases. Her innovative work in nanotechnology and smart drug carriers supports global medical innovation by improving targeted therapy, reducing side effects, and addressing critical healthcare challenges.

Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Okechukwu Obulezi | Blood Cancer | Best Paper Award

Published on by Oncology

Dr. Okechukwu Obulezi | Blood Cancer | Best Paper Award 

Lecturer | Nnamdi Azikiwe Univeristy | Nigeria

Dr. Okechukwu Jeremiah Obulezi, Ph.D., is a distinguished statistician whose academic trajectory, research productivity, and multidisciplinary impact make him exceptionally suitable for a Best Paper Award. With a strong foundation in Statistics from Nnamdi Azikiwe University and Abia State Polytechnic, culminating in a Ph.D. focused on developing innovative generalized distribution families through Logistic-X transformations, he has consistently advanced statistical theory and its applications. His research interests span probability distributions, machine learning models, survival analysis, competing risks, acceptance sampling, optimum sampling, mask data and censoring schemes—areas crucial to modern data-driven decision-making in engineering, biomedical sciences, public health, and socio-economic modelling. Dr. Obulezi’s publication record is extensive and impactful, with over forty peer-reviewed journal articles in reputable outlets such as Heliyon, Scientific African, Alexandria Engineering Journal, Entropy, Symmetry, AIP Advances, and Earthline Journal of Mathematical Sciences. His works introduce new probability distributions, propose enhanced estimation techniques, develop sampling plans, and apply machine learning to real-world problems such as financial volatility, disease survival modelling, COVID-19 mortality, rainfall analysis, transportation cost prediction, and biomedical datasets. His methodological sophistication and ability to translate theory into practical applications underscore his scholarly depth. Professionally, he serves as Lecturer I at Nnamdi Azikiwe University and holds several academic leadership roles, including Seminar & Project Coordinator and member of multiple university committees. His international academic influence is further demonstrated through active service as a reviewer for renowned journals under Springer, Elsevier, Taylor & Francis, and Scopus-indexed platforms. Dr. Obulezi’s conference contributions and book chapter reviews further affirm his commitment to advancing statistical knowledge. Collectively, his robust research output, innovative contributions to distribution theory, interdisciplinary relevance, and sustained scholarly engagement establish him as a highly deserving candidate for the Best Paper Award.

Profile: Google Scholar 

Featured Publications

  1. Onyekwere, C. K., & Obulezi, O. J. (2022). Chris-Jerry distribution and its applications. Asian Journal of Probability and Statistics, 20(1), 16–30.

  2. Chinedu, E. C. Q., Chukwudum, Q. C., Alsadat, N., Obulezi, O. J., Almetwally, E. M., & Others. (2023). New lifetime distribution with applications to single acceptance sampling plan and scenarios of increasing hazard rates. Symmetry, 15(10), 1–33.

  3. Orji, G. O., Etaga, H. O., Almetwally, E. M., Igbokwe, C. P., Aguwa, O. C., & Obulezi, O. J. (2025). A new odd reparameterized exponential transformed-X family of distributions with applications to public health data. Innovation in Statistics and Probability, 1(1), 88–118.

  4. Obulezi, O. J., Anabike, I. C., Oyo, O. G., Harrison, E., & Perpetua, I. C. (2023). Marshall-Olkin Chris-Jerry distribution and its applications. International Journal of Innovative Science and Research Technology, 8(5), 1–15.

  5. Anabike, I. C., Igbokwe, C. P., Onyekwere, C. K., & Obulezi, O. J. (2023). Inference on the parameters of Zubair-Exponential distribution with application to survival times of guinea pigs. Journal of Advances in Mathematics and Computer Science, 38(7), 12–35.

By creating forward-looking statistical frameworks with real-world applications, the nominee’s research bridges science and society, enabling smarter policies, stronger industries, and transformative technological progress.

Xinli Shi | Tumor | Best Researcher Award

Published on by Oncology

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

🏥MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan University—one of China’s top-tier medical schools.

🩺PROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

🏆RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

🔹 Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in China—blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

📊🔬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3